CD19 and neoplasm: To verify the anti-tumor effect of T-CD3εζ28-BiTE.19 in vivo, a CD19 positive xenograft tumor model was established by subcutaneously inoculation of HeLa-CD19 cells into the right flank of nude mice, and T cells were intratumorally injected after three days.